Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Septerna Inc.
Headquarters: San Francisco, CA, United States of America
Website: https://septerna.com/
Year Founded: 2022
Status: Public
Industry Sector: N/A
CEO: N/A
Number Of Employees: N/A
Enterprise Value: N/A
PE Ratio: N/A
Exchange/Ticker 1: NASDAQ:SEPN
Exchange/Ticker 2: N/A
Latest Market Cap: $244,211,504
BioCentury | Feb 20, 2025
Product Development
Solid produces best-in-class biomarker data among DMD gene therapies
BioCentury’s latest Clinical Report highlights a pair of value-driving readouts
BioCentury | Jan 11, 2025
Management Tracks
Faces in new places ahead of JPM: Rubin joining Guggenheim
Week’s management moves include new venture partners at Frazier and updates from Beigene, Intellia and more
BioCentury | Jan 7, 2025
Management Tracks
John Finn named CSO of Basecamp
Plus: Iambic hires Michael Secora and updates from Septerna, Beigene, Perspective, Halia and more
BioCentury | Oct 31, 2024
Finance
Axonis advancing KCC2 program with $115M series A
BioCentury’s Venture Report also includes fundings for Evommune, Blue Earth and more
BioCentury | Oct 25, 2024
Finance
Septerna’s GPCRs draw strong demand in $288M IPO
BioCentury’s Financial Report: ProQR’s $75M raise, Seaport’s $225M series B and more
BioCentury | Oct 4, 2024
Finance
Phase I biotechs Septerna, Orum bolster IPO queue
BioCentury’s Public Equity Report also features Caliway’s IPO, Biohaven’s $287.5M follow-on
BioCentury | Sep 26, 2024
Management Tracks
Draghia-Akli, a veteran of J&J and Merck, joins Novavax as head of R&D
Plus: Septerna expands clinical team and an update from AAM
BioCentury | Apr 10, 2024
Finance
How Goldman Sachs’ life sciences strategy aims to scale private biotechs
Recent investment in Alterome is one of six since 2022 intended to allow biotechs to reach milestones while staying private longer
BioCentury | Jan 4, 2024
Finance
Jan. 3 Quick Takes: Goldman Sachs unveils $650M life sciences fund
Plus: Arrowhead trades up as $450M follow-on extends runway and updates from Remix, CG Oncology, Agios, Boehringer-Ribo, Enyo
BioCentury | Sep 12, 2023
Deals
Sept. 12 Quick Takes: Exelixis takes rights to Insilico’s synthetic lethal molecule
Plus: Vertex, Septerna in GPCR deal and updates from Pierre Fabre, Vertical, Traverse, Genmab, Neurocrine, Rome, CymaBay
Items per page:
1 - 10 of 18